1H-NMR based metabolomic profiling of cord blood in gestational hypothyroidism.
1H-NMR
Gestational hypothyroidism (GHT)
cord blood
metabolomics
prognosis
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
2
5
2020
Statut:
ppublish
Résumé
Gestational hypothyroidism (GHT) is a common pregnancy-related thyroid disfunction. The adverse outcomes by GHT has been increasingly recognized, leading to more public awareness of the disease. However, comprehensive understanding of the prognosis of GHT has not yet achieved. Metabolomics is a powerful tool in evaluation of disease outcomes, and cord blood represents an excellent candidate for the investigation of gestational outcomes. In the present study, we performed 1H-NMR based metabolomics on cord blood of 18 pregnant women with GHT and 18 non hypothyroidism (NHT) control. The metabolomic profile of GHT was separated with the NHT control. A total of 8 metabolites with altered abundances were observed, among which Creatinine and O-Phosphocholine were elevated and the others were downregulated in GHT. Spearman rank correlation suggested that the eight differential metabolites were correlated with the GHT related thyroid hormones. Pathway analysis of the differential metabolites indicated that two metabolic pathways were significantly altered in GHT (adjusted P<0.05), including tyrosine metabolism, phenylalanine, tyrosine and tryptophan biosynthesis. Enrichment analysis of the differential metabolites against disease-associated metabolite sets suggested that GHT was associated with disease risks of non-insulin dependent diabetes mellitus, isovaleric acidemia, and methylmalonic aciduria. The results of this study revealed GHT associated metabolic changes in cord blood, providing insights into the metabolic intermediates between GHT and its related disease risks.
Sections du résumé
BACKGROUND
BACKGROUND
Gestational hypothyroidism (GHT) is a common pregnancy-related thyroid disfunction. The adverse outcomes by GHT has been increasingly recognized, leading to more public awareness of the disease. However, comprehensive understanding of the prognosis of GHT has not yet achieved. Metabolomics is a powerful tool in evaluation of disease outcomes, and cord blood represents an excellent candidate for the investigation of gestational outcomes.
METHODS
METHODS
In the present study, we performed 1H-NMR based metabolomics on cord blood of 18 pregnant women with GHT and 18 non hypothyroidism (NHT) control.
RESULTS
RESULTS
The metabolomic profile of GHT was separated with the NHT control. A total of 8 metabolites with altered abundances were observed, among which Creatinine and O-Phosphocholine were elevated and the others were downregulated in GHT. Spearman rank correlation suggested that the eight differential metabolites were correlated with the GHT related thyroid hormones. Pathway analysis of the differential metabolites indicated that two metabolic pathways were significantly altered in GHT (adjusted P<0.05), including tyrosine metabolism, phenylalanine, tyrosine and tryptophan biosynthesis. Enrichment analysis of the differential metabolites against disease-associated metabolite sets suggested that GHT was associated with disease risks of non-insulin dependent diabetes mellitus, isovaleric acidemia, and methylmalonic aciduria.
CONCLUSIONS
CONCLUSIONS
The results of this study revealed GHT associated metabolic changes in cord blood, providing insights into the metabolic intermediates between GHT and its related disease risks.
Identifiants
pubmed: 32355740
doi: 10.21037/atm.2020.03.91
pii: atm-08-06-296
pmc: PMC7186693
doi:
Types de publication
Journal Article
Langues
eng
Pagination
296Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Diabetes Care. 2015 Sep;38(9):1657-64
pubmed: 26070591
Curr Mol Pharmacol. 2012 Jun;5(2):301-16
pubmed: 22122469
J Pharm Biomed Anal. 2015 Mar 25;107:63-74
pubmed: 25569286
Endocrinology. 1994 Feb;134(2):574-81
pubmed: 8299556
Cancer Manag Res. 2018 Apr 11;10:715-734
pubmed: 29692630
Diabetologia. 2015 Jun;58(6):1329-32
pubmed: 25748329
Int J Mol Sci. 2015 Sep 08;16(9):21520-38
pubmed: 26370975
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
Orphanet J Rare Dis. 2012 Jan 28;7:11
pubmed: 22284844
Thyroid. 2017 Mar;27(3):315-389
pubmed: 28056690
Endocrinology. 2018 Apr 1;159(4):1910-1921
pubmed: 29522169
Autoimmun Rev. 2013 Aug;12(10):1022-30
pubmed: 23688955
Mol Genet Metab Rep. 2017 Mar 17;11:2-5
pubmed: 30547004
Metab Syndr Relat Disord. 2015 Mar;13(2):64-70
pubmed: 25419905
PLoS One. 2017 Nov 2;12(11):e0187545
pubmed: 29095932
Endocrinology. 1969 Dec;85(6):1166-71
pubmed: 5347620
J Matern Fetal Neonatal Med. 2016 Nov;29(21):3416-20
pubmed: 26742853
BMC Syst Biol. 2013 Jul 19;7:62
pubmed: 23870038
Best Pract Res Clin Obstet Gynaecol. 2015 Jul;29(5):700-6
pubmed: 26028555
Endocrine. 2016 Dec;54(3):742-750
pubmed: 27423217
Nature. 1962 Nov 3;196:486-7
pubmed: 14022086
Nefrologia. 2010;30(3):378-80
pubmed: 20514116
Nat Rev Endocrinol. 2012 Feb 14;8(5):260-1
pubmed: 22330742
Rev Endocr Metab Disord. 2018 Mar;19(1):13-33
pubmed: 30198059
Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000588
pubmed: 27148576
Arch Endocrinol Metab. 2016 Feb;60(1):16-20
pubmed: 26331227
Endocrinol Metab Clin North Am. 2019 Sep;48(3):547-556
pubmed: 31345522
Front Neurol. 2018 Dec 18;9:1126
pubmed: 30619076
Endocrinol Diabetes Nutr. 2020 Jan;67(1):36-42
pubmed: 31109823
Front Immunol. 2019 Mar 22;10:527
pubmed: 30967866
Aust Prescr. 2017 Dec;40(6):214-219
pubmed: 29375183
J Affect Disord. 2015 Oct 1;185:156-63
pubmed: 26186531
Crit Care. 2017 Apr 19;21(1):97
pubmed: 28424077
Indian J Physiol Pharmacol. 1993 Jul;37(3):176-82
pubmed: 8276491
Orphanet J Rare Dis. 2014 Sep 02;9:130
pubmed: 25205257
Biochim Biophys Acta. 1977 Feb 4;464(3):620-8
pubmed: 836828
Hepatology. 2013 May;57(5):2072-7
pubmed: 23150189